BTCC / BTCC Square / Global Cryptocurrency /
Trump’s Drug Pricing Policies Face Skepticism Amid Potential Tariff Impacts

Trump’s Drug Pricing Policies Face Skepticism Amid Potential Tariff Impacts

Published:
2025-10-18 13:17:01
14
1
BTCCSquare news:

President Donald Trump's aggressive push to lower pharmaceutical prices through a series of executive actions is drawing scrutiny from economists and industry experts. The latest move—a deal with Pfizer to align Medicaid prices with international benchmarks—may be undermined by proposed 100% tariffs on drug imports, which could inflate costs for generics and domestically produced medications.

The agreement, touted as a model for future manufacturer negotiations, includes discounted direct-to-consumer sales via Trumprx.gov by 2026. Yet critics argue such measures fail to address structural inefficiencies in U.S. drug pricing, where medications often cost multiples of their European counterparts.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.